For the first time, the New England Journal of Medicine published two results of Chinese scholars at the same time: a major breakthrough in the research of Zhou Caicun's team
The 2023 ESMO Annual Meeting hosted by the European Society of Medical Oncology will kick off on October 20, 2023 in Madrid, Spain. On the evening of October 21, cancer research led by Chinese scholars ushered in a historic moment - two international multi-center phase III clinical trials, the LIBRETTO-431 study and the PAPILLON study, led by Professor Zhou Caicun from the Shanghai Pulmonary Hospital Affiliated to Tongji University, were unveiled simultaneously. , two research papers were also published in the New England Journal of Medicine at the same time, with Zhou Caicun ranked as the first author and corresponding author. This is the first time in the field of Chinese cancer research that the same Chinese scholar has published the results of two international multi-center clinical studies in the same journal of NEJM as the first and corresponding author, conveying China's voice and giving Chinese solutions on the highest stage of world medicine.
Results of two international multi-center phase III trials: The PAPILLON study proved that the "evantumumab chemotherapy" regimen can significantly extend the median progression-free survival of advanced non-small cell lung cancer carrying epidermal growth factor receptor exon 20 insertion mutations ; In another phase III LIBRETTO-431 trial that included RET fusion-positive non-small cell lung cancer, seputinib improved the median progression-free survival compared with "platinum-based chemotherapy ± pembrolizumab" More than doubled. These two studies further confirm that timely, comprehensive genomic testing will provide an important basis for initial treatment decisions for all patients with non-small cell lung cancer.
For a long time, there is usually a lack of effective treatment strategies for some rare types of lung cancer. These two studies provide new treatment options for such patients, giving patients more and better treatment options and possibilities. The main manifestations are: first, improving the treatment effect. The first-line treatment strategy for rare targets is expected to make the treatment of these patients more precise and effective, allowing patients to achieve better recovery and quality of life; second, it saves medical resources. Medical resources can be used more effectively and unnecessary examinations and treatments can be avoided for patients who do not require specific treatment; the third is to promote the advancement of medical technology. The identification of rare target treatment strategies can promote progress in the field of clinical basic translation and bring better treatment options to patients; fourth, it provides reference and inspiration. The successful application of rare target treatment strategies can provide reference and inspiration for the treatment of other similar diseases.
"Although advanced non-small cell lung cancer usually requires immediate start of treatment after diagnosis, the results of the two studies further demonstrate the importance of incorporating biomarker testing into the routine diagnosis and treatment process to guide clinical decisions at an early stage and develop the most effective treatment plan." Under the leadership of Zhou Caicun, the oncology team of the Pulmonary Hospital took the lead in discovering lung cancer treatment targets and clinical translation research. The early diagnosis rate of lung cancer increased from 69% to 95%. Molecular testing helped 95% of late-stage lung cancer patients find driver genes. More and more patients are getting a chance of long-term survival under the guidance of hospital treatment plans. In the field of global oncology, the team has established a comprehensive, accurate and fast precision diagnosis and treatment system for lung cancer. From the first diagnosis to the initial establishment of a treatment plan for a patient, it only takes 4 working days, achieving the "China speed" of lung cancer diagnosis and treatment.
"Clinical research is the only way for the high-quality development of the hospital. It is the core link that connects basic research and clinical application and realizes medical technological innovation." Chen Chang, Secretary of the Party Committee of the Pulmonary Hospital, said that the hospital will further introduce new and original basic and clinical research in " Under the concept of "patient-centered, clinical frontline-centered", we focus on the difficulties, pain points, and blockages in people's medical treatment.
![For the first time, the New England Journal of Medicine published two results of Chinese scholars at the same time: a major breakthrough in the research of Zhou Caicun's team](https://a5qu.com/upload/images/a9ced6ecbdf5c8406835573a4192f31e.webp)